RxDoctor Payments Data

Todd Grazia, MD

Pulmonary Disease · Dallas, TXNPI 1184714768

Payments from drug & device makers

$62,241in general payments, 2019–2025

Across 75 payments — averaging $829.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$51K
  • Zambon USA Ltd.$6K
  • Invivyd Inc$3K
  • La Jolla Pharmaceutical Company$835
  • Kamada Ltd.$311
  • Paragonix Technologies, Inc.$299
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$8,03071%
  • Travel & lodging$160%
  • Food & beverage$3,18128%
  • Gifts$270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,241 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$75,623
Medicare patients
117
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$105,739
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5019$96,842
PrevymisLetermovir13$89,241
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$74,800
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$66,723
Valganciclovir Hcl75$20,980
Atovaquone35$20,537
Itraconazole156$20,436
Repatha SureclickEvolocumab18$16,580
ValacyclovirValacyclovir Hcl152$15,776
Posaconazole22$14,078
Sirolimus33$10,873
Voriconazole13$8,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$6,714
Azithromycin239$5,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckPrevymis$278$89,24113 claims
GSKTrelegy Ellipta$35$6,71413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →